COBRE:Eukaryotic Pathogens Innovation Center (EPIC)
COBRE:真核病原体创新中心(EPIC)
基本信息
- 批准号:9261570
- 负责人:
- 金额:$ 213.47万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-04-15 至 2021-03-31
- 项目状态:已结题
- 来源:
- 关键词:AcetatesAfricanAfrican TrypanosomiasisAmebic colitisAneuploidyAreaAssistantshipBiogenesisBiologyBioterrorismCardiovascular DiseasesCell SeparationCenters of Research ExcellenceChagas DiseaseCommunicable DiseasesComplementComplexCore FacilityCryptococcus neoformansDetectionDevelopmentDiagnosisDiseaseDrug resistanceDysenteryEntamoeba histolyticaEnvironmentEnvironmental Risk FactorEquilibriumEquipmentFacultyFaculty RecruitmentFatty AcidsFermentationFluconazoleFosteringFundingFutureGenomicsGlucoseGlycosomeGoalsGovernmentGrantHost DefenseHumanImageIncidenceInfectionInterdisciplinary StudyKnowledgeLeadershipMalariaMass Spectrum AnalysisMedicalMeningitisMentorsMetabolismMicrobial GeneticsModelingOral healthOrganellesParasitic DiseasesParasitic infectionParticipantPathogenesisPeer Review GrantsPhenotypePilot ProjectsProbabilityProgram Research Project GrantsRecruitment ActivityResearchResearch InfrastructureResearch PersonnelResource AllocationRoleScientistSouth CarolinaTalentsTargeted ResearchTrainingTrypanosomaTrypanosoma brucei bruceiUnited States National Institutes of HealthUniversitiesVariantVirulencebasedietary supplementsdrug discoverygenetic evolutionhexokinasehuman diseaseinnovationinsightmembermultidisciplinaryneglected tropical diseasesoxidant stresspathogenprogramspublic health relevanceresistance mechanismsenior facultyskillssuccesstissue regenerationtransmission processvaccine developmentvector
项目摘要
DESCRIPTION (provided by applicant): Eukaryotic pathogens are the causative agents of some of the most devastating and intractable diseases of humans, including malaria, amebic dysentery, sleeping sickness, Chagas disease, and meningitis. The global impact of these diseases is immense. It is noteworthy that many of these pathogens are the causative agents of neglected tropical diseases (NTDs) and/or are also classified as bioterrorism agents. Importantly, infections caused by eukaryotic pathogens are increasing in the US due to globalization. The primary goal of this COBRE proposal is to increase the number of NIH-funded scientists in the state of South Carolina by establishing a world-class research center, the Eukaryotic Pathogens Innovation Center (EPIC), at Clemson University (CU). The scientific focus of EPIC will be a multidisciplinary study of important global eukaryotic pathogens. Five projects from target junior investigators will be supported. Their projects are 1) The role of acetate fermentation in Entamoeba histolytica virulence; 2) Glycosome biogenesis in African trypanosomes; 3) Glucose Sensing and Hexokinases in the African Trypanosome; 4) Fatty acid synthesis in Trypanosoma brucei, and 5) Exploring the mechanisms of fluconazole-induced aneuploidy in Cryptococcus neoformans. These investigators will be matched with mentors who are established NIH-funded researchers. The projects will be supported by a well-organized Administrative Core and two state-of-the-art Scientific Cores in Genomics, Imaging and Cell Sorting, and Mass Spectroscopy. The Scientific Cores will also benefit at least two other COBRE-funded centers in the state of South Carolina and other faculty at CU. The center also has a substantial infrastructure base and significant institutional support. For example, CU will recruit three additional investigators to expand activities of this center over the course of the project period. Pledges of graduate assistantships, equipment, and space further exemplify the institutional commitment. This COBRE-funded center will significantly expand research in South Carolina and will facilitate recruitment, training, and retention of a critical mass of investigatos with cross-disciplinary skills in this important research area.
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
LESLY A TEMESVARI其他文献
LESLY A TEMESVARI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('LESLY A TEMESVARI', 18)}}的其他基金
COBRE:Eukaryotic Pathogens Innovation Center (EPIC)
COBRE:真核病原体创新中心(EPIC)
- 批准号:
9900800 - 财政年份:2016
- 资助金额:
$ 213.47万 - 项目类别:
Stress Induced Control of Protein Translation in Entamoeba Histolytica
应激诱导的溶组织内阿米巴蛋白质翻译控制
- 批准号:
8664552 - 财政年份:2014
- 资助金额:
$ 213.47万 - 项目类别:
A forward genetics screen for genes regulating phagocytosis and signaling in Enta
Enta 中调节吞噬作用和信号传导基因的正向遗传学筛选
- 批准号:
7573223 - 财政年份:2009
- 资助金额:
$ 213.47万 - 项目类别:
A forward genetics screen for genes regulating phagocytosis and signaling in Enta
Enta 中调节吞噬作用和信号传导基因的正向遗传学筛选
- 批准号:
7876802 - 财政年份:2009
- 资助金额:
$ 213.47万 - 项目类别:
Role of lipid rafts and phosphoinositides in E. histolytica virulence
脂筏和磷酸肌醇在溶组织内阿米巴毒力中的作用
- 批准号:
7652365 - 财政年份:2001
- 资助金额:
$ 213.47万 - 项目类别:
相似海外基金
The catalytic core of the proteasome as a drug target to treat Human African Trypanosomiasis
蛋白酶体的催化核心作为治疗非洲人类锥虫病的药物靶点
- 批准号:
10511408 - 财政年份:2022
- 资助金额:
$ 213.47万 - 项目类别:
A One Health approach to investigating the ecology of East African trypanosomiasis in Malawian wildlife
调查马拉维野生动物中东非锥虫病生态学的“同一个健康”方法
- 批准号:
476178 - 财政年份:2022
- 资助金额:
$ 213.47万 - 项目类别:
Studentship Programs
The catalytic core of the proteasome as a drug target to treat Human African Trypanosomiasis
蛋白酶体的催化核心作为治疗非洲人类锥虫病的药物靶点
- 批准号:
10677879 - 财政年份:2022
- 资助金额:
$ 213.47万 - 项目类别:
Multi-target approach to rational design of novel therapeutics for human African trypanosomiasis
多目标方法合理设计非洲人类锥虫病新疗法
- 批准号:
10466942 - 财政年份:2021
- 资助金额:
$ 213.47万 - 项目类别:
Multi-target approach to rational design of novel therapeutics for human African trypanosomiasis
多目标方法合理设计非洲人类锥虫病新疗法
- 批准号:
10296873 - 财政年份:2021
- 资助金额:
$ 213.47万 - 项目类别:
Multi-target approach to rational design of novel therapeutics for human African trypanosomiasis
多目标方法合理设计非洲人类锥虫病新疗法
- 批准号:
10706306 - 财政年份:2021
- 资助金额:
$ 213.47万 - 项目类别:
Reducing and replacing the animal cost of functional genetics in African trypanosomiasis
减少和替代非洲锥虫病功能遗传学的动物成本
- 批准号:
NC/W001144/1 - 财政年份:2021
- 资助金额:
$ 213.47万 - 项目类别:
Research Grant
Development of new drug for African trypanosomiasis based on elucidation of the mechanism of antiprotozoal action by ribavirin.
基于利巴韦林抗原虫作用机制的阐明,开发治疗非洲锥虫病的新药。
- 批准号:
21K18230 - 财政年份:2021
- 资助金额:
$ 213.47万 - 项目类别:
Grant-in-Aid for Challenging Research (Pioneering)
Development of a novel control measure for African trypanosomiasis based on the blocking of lifecycle progression
基于生命周期进展阻断的非洲锥虫病新型控制措施的开发
- 批准号:
20K07467 - 财政年份:2020
- 资助金额:
$ 213.47万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Drug-diagnostic co-development in Tropical Medicine, combating Human African Trypanosomiasis
热带医学药物诊断联合开发,抗击非洲人类锥虫病
- 批准号:
18KK0454 - 财政年份:2019
- 资助金额:
$ 213.47万 - 项目类别:
Fund for the Promotion of Joint International Research (Fostering Joint International Research (A))